Equities research analysts expect Voyager Therapeutics Inc (NASDAQ:VYGR) to announce $2.90 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Voyager Therapeutics’ earnings. The highest sales estimate is $5.00 million and the lowest is $2.00 million. Voyager Therapeutics reported sales of $6.35 million in the same quarter last year, which indicates a negative year over year growth rate of 54.3%. The business is expected to report its next quarterly earnings report on Wednesday, March 13th.

On average, analysts expect that Voyager Therapeutics will report full-year sales of $8.86 million for the current financial year, with estimates ranging from $7.61 million to $11.15 million. For the next year, analysts anticipate that the company will report sales of $23.08 million, with estimates ranging from $8.00 million to $68.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.15. The firm had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $3.02 million. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%.

A number of brokerages recently commented on VYGR. BTIG Research lowered their price objective on shares of Voyager Therapeutics to $23.00 and set a “positive” rating on the stock in a research note on Tuesday. BidaskClub cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 20th. Wedbush reissued an “outperform” rating and issued a $28.00 price objective (up from $18.00) on shares of Voyager Therapeutics in a research note on Thursday, November 8th. HC Wainwright set a $25.00 price objective on shares of Voyager Therapeutics and gave the company a “buy” rating in a research note on Friday, November 9th. Finally, Zacks Investment Research raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Saturday, November 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $25.56.

NASDAQ VYGR traded down $0.16 during trading hours on Friday, reaching $9.10. The company’s stock had a trading volume of 185,000 shares, compared to its average volume of 251,065. The stock has a market cap of $307.99 million, a price-to-earnings ratio of -3.45 and a beta of 2.73. Voyager Therapeutics has a fifty-two week low of $8.30 and a fifty-two week high of $31.91.

A number of large investors have recently added to or reduced their stakes in the business. Teachers Advisors LLC lifted its holdings in Voyager Therapeutics by 7.9% in the 3rd quarter. Teachers Advisors LLC now owns 49,465 shares of the company’s stock valued at $936,000 after purchasing an additional 3,621 shares in the last quarter. Vanguard Group Inc lifted its holdings in Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after purchasing an additional 113,442 shares in the last quarter. Marshall Wace LLP purchased a new position in Voyager Therapeutics in the 3rd quarter valued at about $1,112,000. Vanguard Group Inc. lifted its holdings in Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after purchasing an additional 113,442 shares in the last quarter. Finally, Standard Life Aberdeen plc purchased a new position in Voyager Therapeutics in the 3rd quarter valued at about $660,000. Institutional investors own 88.57% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Read More: What is the NASDAQ?

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.